Moderna, Inc. (NASDAQ:MRNA) President Sells $12,451.89 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 291 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $12,451.89. Following the transaction, the president now owns 1,443,567 shares of the company’s stock, valued at approximately $61,770,231.93. The trade was a 0.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Stephen Hoge also recently made the following trade(s):

• On Tuesday, September 3rd, Stephen Hoge sold 318 shares of Moderna stock. The stock was sold at an average price of $76.99, for a total transaction of $24,482.82.

Moderna Trading Up 2.8 %

Shares of Moderna stock traded up $1.20 during trading hours on Monday, reaching $44.26. 6,740,633 shares of the company’s stock were exchanged, compared to its average volume of 4,892,647. The firm has a market capitalization of $17.03 billion, a price-to-earnings ratio of -7.40 and a beta of 1.69. The company has a fifty day moving average of $52.38 and a 200-day moving average of $90.84. Moderna, Inc. has a 52-week low of $35.80 and a 52-week high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the previous year, the firm earned ($1.39) earnings per share. Moderna’s revenue was up 3.8% compared to the same quarter last year. Sell-side analysts forecast that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MRNA shares. Bank of America lowered their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday, September 13th. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Barclays cut their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a report on Monday, November 18th. Finally, Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $83.33.

Hedge Funds Weigh In On Moderna

A number of large investors have recently modified their holdings of MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna during the 2nd quarter worth $26,000. Family Firm Inc. acquired a new stake in shares of Moderna in the second quarter valued at about $33,000. Bank & Trust Co purchased a new stake in shares of Moderna during the 2nd quarter valued at about $36,000. Hanseatic Management Services Inc. purchased a new position in Moderna in the 2nd quarter worth approximately $48,000. Finally, Plato Investment Management Ltd raised its stake in shares of Moderna by 230.4% during the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after purchasing an additional 288 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.